Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE Populations of endometrial and endometriotic epithelial cells also harbor multiple cancer driver mutations, such as KRAS, which may be associated with the establishment of pelvic endometriosis or ovarian cancer. 30994890

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Preliminary evidence of clinical activity was observed with gedatolisib plus PD-0325901 in patients with ovarian cancer (three partial responses, n = 5) or endometrial cancer (one partial response, n = 1) and KRAS mutations. 29067643

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors. 28992761

2017

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE VEGF concentrations in ascites significantly increased in c-MYC-induced ovarian cancer, whereas the concentrations of inflammatory cytokines in ascites were significantly high in KRAS-induced ovarian cancer and were accompanied by an increased number of neutrophils in ascites. 27483433

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE Reintroducing KRAS rescued the inhibitory effects exerted by miR-613 on ovarian cancer cell proliferation and invasion. 26631045

2016

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE Our results define the RAS/MEK/DNMT1 pathway as a determinant of sensitivity to DNA methyltransferase inhibition, specifically implicating KRAS status as a biomarker of drug response in ovarian cancer. 25968887

2015

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE Together, REDD1 and p-AKT over-expression may serve as a prognostic biomarker in OC, but KRAS mutations and REDD1 protein over-expression were not correlated in OC. 25337238

2014

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE The results from this study confirm previously demonstrated associations of KRAS mutations with well-differentiated and mucinous ovarian carcinomas. 23800114

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Additionally, RAS/RAF/MEK/ERK pathway-targeted therapy may benefit selected patients with type II ovarian carcinoma harboring KRAS/MAPK1 amplifications. 23820584

2013

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. 22662244

2012

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE An assay for the single-nucleotide polymorphism (SNP), rs61764370, has recently been commercially marketed as a clinical test to aid ovarian cancer risk evaluation in women with family histories of the disease. rs67164370 is in a 3'-UTR miRNA binding site of the KRAS oncogene and is a candidate for epithelial ovarian cancer (EOC) susceptibility. 21385923

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families. 20676756

2011

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Our findings strongly support the hypothesis that the KRAS-variant is a genetic marker for increased risk of developing OC, and they suggest that the KRAS-variant may be a new genetic marker of cancer risk for HBOC families without other known genetic abnormalities. 20647319

2010

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Mutations in the KRAS gene are one of the most frequent genetic abnormalities in ovarian carcinoma. 19358724

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 Biomarker BEFREE We found no evidence of disease association for SNPs in BRAF, KRAS, ERBB2 and PIK3CA when OC was considered as a single disease phenotype; but after stratification by histological subtype, we found borderline evidence of association for SNPs in KRAS and BRAF with mucinous OC and in ERBB2 and PIK3CA with endometrioid OC. 19240718

2009

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Next, to clarify the roles of ERK1/2 activation in ovarian cancers harbouring KRAS or BRAF mutations, we inactivated ERK1/2 in ovarian cancer cells using CI-1040. 19018267

2008

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways. 12644542

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. 12893203

2003

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE Thus, K-RAS mutations at codon 12 and 6q27 LOH were suggested to be involved in the development and/or progression of mucinous ovarian carcinoma and serous ovarian carcinoma, respectively. 10748293

2000

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 AlteredExpression BEFREE This suggests that mutation of the nm23 genes and the K-ras gene affects carcinogenesis or progression of ovarian carcinoma by modulating expression of the nm23 genes. 7669582

1995

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.700 GeneticVariation BEFREE A cell line from a human ovarian carcinoma with amplification of the K-ras gene. 3756872

1986